3 Biotech Stocks Ripe for Spring Portfolio Cleaning

3 Biotech Stocks Ripe for Spring Portfolio Cleaning
Patrick Bafuma, The Motley Fool
·6 min read

This April, many previous growth stocks have cooled, and the biotech sector is no exception. FibroGen (NASDAQ: FGEN), Novavax (NASDAQ: NVAX), and Editas Medicine (NASDAQ: EDIT) have all taken a beating for various reasons. It usually is not a reassuring sign to see that, right before going in front of the U.S. Food and Drug Administration (FDA) for review, a company wants to clarify prior data in regards to cardiovascular safety.